Atlanta Center for Medical Research | Atlanta, GA
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.
Full description
The study consists of different parts. Part A of the study will consist of once daily (OD) cohorts (OD Cohort 1 to 4[5]), as well as twice daily (BID) cohorts (BID Cohorts A1 and A2). Part B and Part C have been added to the study. Part B will consist of 2 cohorts (Cohorts B1 and B2) whereby participants will be administered Lu AF28996 BID. Part C will consist of 2 cohorts (Cohorts C1 and C2) whereby participants will be administered three times daily (TID) Lu AF28996.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Part A
Part B and Part C
Exclusion criteria
Other inclusion and exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
77 participants in 1 patient group
Loading...
Central trial contact
Email contact via H. Lundbeck A/S
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal